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Abstract
The current study explores the first case of the implementation of solution calorimetry (SolCal) in order to determine the amorphous
content of crystalline benzoyl-methoxy-methylindol-acetic acid (BMA)—a model poorly soluble drug, in the amorphous granules
prepared via single-step continuous twin-screw dry granulations (TSG). Amorphous magnesium aluminometasilicate (Neusilin®)
(US2) was used as a novel inorganic carrier via a TwinLab 10 mm twin-screw extruder. The BMA/US2 blends were processed at
180 °C and varying drug: carrier ratios of 1:4, 1:2.5 and 1:1 (w/w). Physico-chemical characterisation conducted via SEM,DSC and
XRPD showed amorphous state of the drug in all granulated formulations. Reverse optical microscopy revealed a meso-porous
structure of US2 in which the drug particles are adsorbed and/or entrapped within the porous network of the carrier. This
phenomenon can be the underlying reason for the increase of the amorphous content in the extruded granules. Solution calorimetry
(SolCal) study revealed amorphous content of the drug in all formulations quite precisely, whereas the dynamic vapour sorption
(DVS) analysis complemented the results from SolCal. Furthermore, an attempt has been made for the first time to interrelate the
findings from the SolCal to that of the release of the drug from the amorphous granules. It can be concluded that SolCal can be used
as a novel technique to precisely quantify and interrelate the amorphous content to its physico-chemical performances such as drug
release from the granulated formulations processed via TSG.
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Introduction
It has been reported that about 40% of the new lead com-
pounds found in the drug discovery pipeline are becoming
unsuitable due to its inherent poor water solubility or insol-
ubility issue [1, 2]. Thus, solubility enhancement of these
poorly water-soluble drugs remains a fundamental chal-
lenge for the pharmaceutical scientists across the industry.
Despite numerous studies on advanced manufacturing pro-
cesses, there seems to be no versatile technique currently
available that can tackle this growing solubility issue for all
drugs. There have been various methods and approaches
reported to increase the solubility thus the dissolution rates
of the poorly water soluble drugs such as hot spin mixing
[3], spray drying [4], co-evaporation or co-precipitation [5],
freeze-drying [6], supercritical fluid processing (SFP) [7],
hot-melt extrusion (HME) and recently twin-screw granula-
tions (TSG) using HME techniques [8, 9]. The ultimate aim
of the majority if not all of these reported techniques is to
obtain an amorphous solid of the drug candidate due to the
fact that amorphous forms of crystalline counterpart have
always been appeared as an evolving phenomenon in phar-
maceutical sciences [10]. Amorphous form of a drug gen-
erally appears in more highly energetic state compared to
the crystalline form which often proves beneficial in in-
creasing solubility and thus bioavailability [11, 12].
Recently, twin screw granulations (TSG) have attracted
considerable attention especially in the area of pharmaceutical
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past decades or so have mainly described the production of
semi-crystalline granules or agglomerates via two major ex-
trusion granulation techniques: (i) wet, and (ii) hot melt or dry
granulation [11–14]. The latter being more suitable for the
continuous operation as it eliminates intermediate steps by
producing free-flowing ready-to-use granules [12]. These
granules then can be incorporated into the final dosage forms
such as tablets. However, a suitable formulation has to be
developed in order to process any challenging molecules such
as heat-sensitive excipients like vitamins or proteins.
Recently, a new developed concept of one step continuous
solvent-free extrusion (a process where hot dry extrusion is
performed in the presence of an absorbent instead of water)
via continuous HME processing has been reported [12]. In
this approach, inorganic excipients such as Neusilin® and/or
Fujicalin® can be used as novel inorganic carriers [10, 15–17]
to produce amorphous drug-containing granules almost in
free-flowing ready-to-use nature [11, 12]. In this process, in-
organic carrier can also be used to manufacture homogenous
one phase amorphous systems when combined with a hydro-
philic polymer such as HPMC [11].
Previous studies show that X-ray diffraction has largely
been used to quantify the amorous content in various for-
mulations both quantitatively and qualitatively [12, 13].
Similarly, solution calorimetry (SolCal) can be used as
an ideal technique to quantify the amorphous content in
the granules prepared via TSG which is to the best of our
knowledge, has not been done before. SolCal refers to the
determination of heat of solution when a solid is dissolved
in a liquid, or two liquids are mixed. The software in
solution calorimetry technique uses heat balance equations
[18] to determine the change in enthalpy from the change
in offset temperature as a function of time. Various reports
have been published [19–21] undertaking research with
solution calorimetry using sucrose, lactose, their physical
form especially crystalline or amorphous, their water con-
tents, calibration plot, etc. A study demonstrated heat of
solution of carbamazepine (CBZ) and later [22] relative
enthalpy of formation of co-crystals of CBZ: SAC
(saccharin) elsewhere. Later in 2013, Majumder et al. have
carried out extensive work with solution calorimetry and
demonstrated heat of solution of different co-crystal sys-
tems using different physical forms of the starting mate-
rials [23]. This technique is capable of determining the
amorphous content in the formulation more accurately
and precisely, but somewhat surprisingly, the widespread
use of this innovative technology in amorphous granules
prepared via continuous TSG has not been explored yet.
Thus, the aim of the current study is to implement SolCal to
determine amorphous content of benzoyl-methoxy-
methylindol-acetic acid (BMA)—a model poorly soluble BCS
class II and highly crystalline drug, in the granules prepared via a
continuous twin-screw dry granulations. An attempt has also
been made for the first time to interrelate the findings from the




Benzoyl-methoxy-methylindol-acetic acid (> 99% purity)
(BMA) was purchased from Sigma-Aldrich (Batch#
056K1563, Gillingham, UK), and Neusilin US2 (US2) was
kindly donated by Fuji Chemical Industries Co., Ltd. (Japan).
All solvents used were of analytical grade and used as
received.
Continuous twin-screw dry granulation (TSG)
All granules were prepared via adopting the method de-
scribed by Maniruzzaman et al. in a previous report with
slight modifications [12]. Briefly, all prepared drug/carrier
binary mixtures were processed at 180 °C without the die
using a twin-screw (L/D 40) extruder (TwinLab 10, Twin-
Tech Extrusion Limited, UK). The temperature profiles,
screw speed and the torque were recorded for each proc-
essed sample. The screw speed used for extrusion was
optimised at 100 rpm with a feed rate of ∼0.5–1 kg h−1
that resulted in a short residence time of about ~ 45 s. The
TwinLab 10 is contacted to a terminal HMI (Omron), and
all processing parameters were controlled through the ap-
propriate software supplied by the manufacturer. US2/
BMA ratios were optimised at 4, 2.5 and 1 (w/w) for
TSG operation in order to obtain the final granules. The
extrudates were optimised and collected in powder forms
so that no additional down streaming processing was
required.
Scanning electron microscopy (SEM) and optical
microscopy
The surface morphology of the granules was studied via an
SEM. For this purpose, the samples were mounted on an
aluminium stage using adhesive carbon tape and placed in
a low humidity chamber prior to analysis. Microscopy was
performed using a JEOL JMS 820 (Freising, Germany)
SEM machine with an operating accelerating voltage of
5 kV. Reverse optical microscopy (JEOL JEM1400-Plus,
120 kV, LaB6) was also utilised to investigate the surface
of the granules by applying blue, and red filters to visualise
the particles as desired. Transmission and fluorescent lights
were used to reveal the absorbance, and excitement capa-
bilities of the particles.
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Particle size analysis
Particle size distribution analysis was conducted using a laser
diffraction particle size analyser (Sympatec Ltd., UK)
equipped with the HELOS sensor and Windox software and
was used with the RODOS (dry) system. Detection of the
particles was done using the R3 and R5 lenses, which have a
particle size detection range of 0.5–175 and 0.5–875 μm,
respectively.
Solid state analysis
The solid state of the drug in the granules was investigated
using a Mettler-Toledo 823e (Greifensee, Switzerland) differ-
ential scanning calorimeter (DSC). Approximately, 3-5 mg of
samples was placed in sealed aluminium pans without lids
prior to heating the samples at 10 °C min−1 from 0 to
220 °C under dry nitrogen atmosphere. All samples were
reheated at the same heating rate and were run in triplicate.
The results shown represent the mean.
X-ray powder diffraction (XRPD) was used to determine
the crystalline state of the drug in the granulated formulations
using X-ray diffractometer (D5000, Siemens, Germany).
Samples were scanned over a range of 2θ at voltage of
40 kVand current of 30 mA, with scanning angle ranged from
5° to 40° and scan rate of 0.2° s−1.
FTIR analysis
FTIR analysis was performed on the bulk drug, US2, drug/
carrier physical mixtures and the manufactured granules in
order to assess any possible drug excipient interactions
using a PerkinElmer PE1600 (Massachusetts 02451,
USA) Fourier transform infrared spectrometer via
obtaining KBr disc method. The disc was prepared from
the powders by pressing it for 5 min in a constant pressure
with the aid of a hydraulic press. The spectra were acquired
from 400 to 3600 wavelength cm−1 range. All samples
were run triplicate and the results shown represent the
mean value.
Dynamic vapour sorption (DVS) analysis
Approximately 25 mg of sample was placed into a glass
balance pan and loaded into a DVS Advantage System
(SMS) held at 25 ± 0.1 °C. The sample was then subjected
to a step profile change from 0 to 90% RH (P/Po, whereby
P = partial pressure of water vapour and Po = equilibrium
vapour pressure of water) at 10% RH increments, followed
by desorption from 90% RH to 0% RH at 10% RH decre-
ments maintaining the sample at drying step at 25 °C. The
weight change during the sorption cycle was then moni-
tored, allowing for the hygroscopic nature of the sample to
be determined. The % RH was maintained by the mixture
of DI water and dry nitrogen (flow rate of 200 sccm) which
acted as a wet purge and dry purge, respectively. The per-
centage of mass change per minute (dm/dt) was set as
0.002 with a minimum stability for 30 min, and maximum
stage time was 240 min at each % RH.
Solution calorimetry
A glass ampoule containing 100 mg ± 1 mg of the sample
(accurately weighed) was sealed with a silicon bung and
further sealed using molten beeswax. The ampoule was
then loaded into the stirrer unit of the solution calorimeter.
This unit was then lowered into the glass vessel containing
exactly 100 ml of solvent (DMSO in this case) with the
glass ampoule isolating the solute from the solvent. The
combined unit was then lowered into the experimental
chamber for equilibration prior to the experiment, with
the stirrer speed set at 500 rpm. The solvent was heated
to − 180 mK (offset temperature using the inbuilt heater)
by applying heater power of 500 mW. Calibrations of
500 mW/10 s (= 5 J) were applied before and after the
break with baselines of 5 min before and after, a break time
of 5 min was used, with a baseline of 5 min after. Once an
exponential fit over a 5 min period with a standard devia-
tion of less than 10 μK had been attained, the experiment
was then conducted and the resulting heat of solution de-
termined. Dissolution of the sample was performed by
breaking the ampoule. The heat of solution was reported
in joules per gram. The instrument is calibrated quarterly
using crystalline and amorphous sucrose in de-ionised wa-
ter (DI water) for endothermic and exothermic reactions,
respectively.
Results and discussion
Continuous granulations and the particle morphology
The final optimised processing temperature of the extruded
granules was set at 180 °C, as previously, this temperature
was found most appropriate in order to process and obtain
amorphous granules [12]. The unique formulation composi-
tions and the drug/carrier miscibility produced a completely
homogenous system in a free-flowing granulated forms. This
could be attributed to the high flowability (Carr’s index above
10) of US2 that contains Al2O3 (~ 30%) enabling it to adsorb
the BMA molecules and thus dry up the whole system and
eventually evacuate the extrudates in free-flowing powder
forms [12]. It has been reported that the tetrahedron or
octahedron-shaped Al2O3 forms a complex three-
dimensional structure in US2 making the compound an excel-
lent proton donor or acceptor [24]. As a result, US2 facilitates
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a completely dry blending process in extrusion which can add
a new insight for pharmaceutical research and development
when TSG is involved by eliminating any further down
streaming processing steps. Whilst the down streaming pro-
cessing during a typical HME is considered as one of the
major drawbacks, can perhaps, be remarkably absent in fore-
going process making this innovative idea to enjoy a resur-
gence in the future formulation strategy when US2 is used as a
novel carrier excipient.
The surface morphology of the produced granules exam-
ined via SEM showed no drug crystals on the extrudate sur-
face. Rather, it showed agglomerated granules in irregular
shapes. There was also no evidence of the different phases
in any of the granules which could be attributed to the inten-
sive high shear mixing during the processing. Also, this could
be related to the drug entrapment into the meso-porous US2
network with high specific surface area (300 m2 g−1) during
the processing. Interestingly, at a very high resolution, the
particle size has dramatically fallen into nanoscale (Fig. 1)
and the granules are more agglomerates of nano-sized parti-
cles. This foregoing phenomenon can eventually be of great
interests in oral drug delivery systems and thus opening a new
scope of utilising nano-technology via TSG approach.
Reverse optical microscopy examined the surface mor-
phology of the granulated particles. As can be seen in Fig. 2,
the fluorescent particles of US2 present in the formulations are
spherical and porous. There are some particles adsorbed on
the surface of fluorescent spherical particles which could be
the drug particles. These images also show the homogeneous
distribution and uniformity of drugs within the carrier matrices
in all of the formulations. In general, at a molecular level,
absorbance relates to energy status of the particles and their
ability to excite the electrons within their orbital. As a result, it
is seen that the US2 particles are porous, and BMAmolecules
may have been adsorbed or entrapped within the porous struc-
ture of US2.
The particle size distribution and d10, d50 and d90 values
were determined for all extruded granules. As depicted in
Fig. 3, data obtained from the analysis showed the particle
sizes lower than 115 μm for all formulations which is quite
similar to that of US2 (d90 130μm). In contrast, the bulk BMA
showed very fine particles with a narrow mono-modal distri-
bution and d90 22 μm. A small percentage can be seen at sizes
> 300 μm due to some agglomerates produced during the
granulation process. Nevertheless, all extruded granules were
within the range suitable for the oral solid dosage forms and
showed excellent flow properties.
Solid state analysis
The solid state of the bulk compounds, physical mixtures
(PM) and the extruded granulated formations were examined
via DSC. The DSC thermograms of bulk BMA showed sharp
melting transitions at ~ 162.1 °C with a fusion enthalpy (ΔH)
Fig. 1 SEM images of US2 bulk
and BMA/US2 extruded granules
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of about ~ 101.1 J g−1 (Fig. 4). The analysis of the combined
heat flow of the bulk MAS showed no crystalline melting
endotherms indicating its amorphous nature [25, 26]. All
drug–carrier physical mixtures exhibited sharp melting transi-
tions at slightly shifted towards lower temperature in the range
of 150–155 °C corresponding to the melting of the crystalline
BMA. The heat of fusion increased with the increase of the
drug content in the formulations. For example, US2 4 (20%
BMA) showed an enthalpy (ΔH) of ~ 11 J g−1, whereas US2 1
(50% drug) showed ΔH of about ~ 29 J g−1 which is in line
with the theoretical calculations. In contrast, there were no
endotherms observed in any of the extruded granules. The
absence of melting transitions corresponding to BMA in all
of the formulations indicates the absence of the crystalline
BMA and thus the development of amorphous system [26].
Moreover, the absence of multiple Tgs in the formulations
indicates that the drug is entrapped within the porous network
of the inorganic carrier US2, as the Tg of the US2 is well
above the temperature range used in this study (~ > 300 °C).
Nonetheless, it can be claimed that the US2 can successfully
be used as a novel inorganic carrier tomanufacture amorphous
drug-containing granulated formulations.
Furthermore, the US2-based extruded granules, bulk drug
and the corresponding physical mixtures of the same compo-
sitions were studied by X-ray analysis in order to examine the
crystallinity of the drug in the formulations. All diffractograms
were recorded to examine BMA crystalline state. As can be
seen in Fig. 5, the diffractogram of bulk BMA showed distinct
characteristic intense peaks at various 2θ positions indicating
that the BMA is highly crystalline. Similarly, the physical
mixtures of all BMA formulations showed identical but low
intense peaks suggesting that the drug retains its crystallinity
in the physical blends. In contrast, no distinct intensity peaks
were observed in the diffractograms of the extruded formula-
tions even at high drug loadings e.g. in US2 1 with 50% w/w
drug. The absence of BMA intensity peaks indicates the pres-
ence of its amorphous state or molecularly dispersed state into
the US2 matrices after the granulation process was optimised.
The results obtained in the XRPD complement the findings
from DSC analysis.
Fig. 2 Fluorescence microscopic images of BMA/US2 granules produced via HME
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Fig. 3 Particle size distribution of extruded formulations processed via dry granulations processing. a US2 4. b US2 2.5. c US2 1
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FTIR analysis
The drug BMA contains both phenyl carbonyl and carboxylic
acid groups in the structure (Fig. 6) [12, 26]. The FTIR spectra
of the crystalline BMA showed the acid dimer peak at 1720
and at 1690 cm−1, respectively (Fig. 6). In addition, the peak at
1585 cm−1 was attributed to the benzoyl carbonyl group at-
tached to a nitrogen atom. The absorbance of the drug dimer
peaks disappeared after the granulation process was optimised
in all formulations, and only one slightly shifted peak at
1680 cm−1 was visible. This could be attributed to the inter-
molecular interactions associated with crystalline BMA.
Interestingly, the increase in the concentration of the drug in
formulations showed an increase in the intensity of the char-
acteristic peak at 1680 cm−1 which could be due to the pres-
ence ofmore NH– in the formulation as it only is present in the
BMA. Previous study revealed that owing to the close prox-
imity of the pKa values of SiO2 to that of BMA, the silanol
Fig. 4 DSC transitions of bulk BMA, US2, physical blends of the formulations and extruded granules
Fig. 5 XRPD diffractograms of bulk BMA, US2 and all BMA/US2 formulations
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group from US2 can become amphoteric, functioning as a
Bronsted acid or as a Bronsted base [12, 27]. Therefore, due
to the local electronegativities of –COOH and –Si-OH from
the drug and US2, respectively –C-O-Si is formed as a result
of ionic bonding. These foregoing claims have been outlined
in the molecular modelling predictions as depicted in Fig. 6.
As can be seen in the image, depending on the initial position-
ing of the BMA molecule, multiple bonding patterns were
identified. However, after energy optimisation, the highest
proximity has been observed for the interaction between the
silanol group of the carrier and the carboxyl group of the drug
(~ 4.07 Å). It has also been outlined that both the carbonyl
group and amine group within the drug molecule could form
bonds (e.g. non-covalent H bonds) with the –Si-OH group in
the BMA, as indicated by the optimal distances between the
bond donor and acceptor ~ 15.08 and ~ 11.50 Å, respectively.
Also, the benzoyl carbonyl peak at 1585 cm−1 becomes
broader as a function of decreasing drug concentrations, in-
dicating increasing amorphicity of BMA. It can be claimed
that the higher the BMA amount, the sharper the benzoyl
carbonyl peak thus stronger the interactions. The high
intense stretch at 1680 cm−1 in US2 1 where the drug con-
tent is the highest (50% w/w) indicates that intermolecular
interactions are favoured with the increase in the BMA con-
centration. In contrast, as expected, the characteristic dimer
peaks of BMA are present at the same position for all PM
formulations (data not shown).
DVS analysis
The DVS data presented in Fig. 7a, b showed that the US2
2.5 BMA (~ 30% w/w) formulation sample desorbed ca. 4%
w/w moisture at 0% RH suggesting that the sample already
contained this moisture. This is confirmed by the water up-
take phenomenon, ca. 4% w/w up to 50% RH, which im-
plies that at ambient condition, this sample is hygroscopic.
The hygroscopic nature is also confirmed by the hygroscop-
icity classification as per the Ph. Eur. in Table 1 [28]. So, a
care must be taken to formulate and store this sample after
production during future developmental work. A further wa-
ter uptake up to 6% w/w at 80% RH, followed by a sharp
increase in weight gain up to ca. 10% w/w, which even did
Fig. 6 a FTIR spectra of bulk BMA, US2 and all extruded formulations. b Molecular modelling of the drug and excipient to outline the possible
interactions
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not reach equilibrium, demonstrates that this sample has an
affinity to absorb large quantity of moisture upon exposure
to high humidity. Interestingly, no weight loss was observed
to suggest crystallisation of an amorphous material, due to
water acting as a plasticiser, indicating that water is not a
good plasticiser for this material. Importantly, this implies
that this formulation could be a stable one over a long period
of time at high humidity if water absorption is controlled.
The sample did not hold onto any gained mass during de-
sorption cycle suggesting that the sample is possibly non-
porous in nature and post-DVS sample also did not show
any obvious physical appearance change. Similar results
were obtained for other formulations. The effect of the mois-
ture on the solid state of the extruded granules showed that
the manufactured formulations are stable even at higher drug
concentration (up to 50% w/w).
Fig. 7 a Water sorption isotherms of formulation US2 4. b Water sorption kinetics of formulation US2 4
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Solution calorimetry (SolCal)
The solution calorimetry data presented in Table 2 suggested a
reproducible data set for a biphasic system. It clearly demon-
strates and distinguishes heat of solution of different materials.
There are two interesting aspects of these data set: the first one
being all formulation samples with different % w/w of the API
loading showed a response which is different to physical mix
(theoretically expected), and had there been a physical mix made
for those formulation samples as their theoretical response were
different than the experimental response sugggesting that the
formulations were indeed not a mere physical mix. This hypoth-
esis is effectively validated by the data obtained for 50:50 (w/w)
physicalmix (PM) betweenBMAandUS2. The second aspect is
that the US2 1 with 50% w/w drug did not follow the expected
trend as the other US2 4 andUS2 2.5 samples suggesting that the
API load was optimised up to ~ 30% w/w or in between 30 and
40% w/w.
Generally, amorphous samples exhibit exothermic re-
sponse; it is possible that the US2 2.5 sample is higher in
amorphous nature than its US2 4 and US2 1 counterparts.
However, the reason could be different in both cases.
Based on these data, the relationship between 20% w/w
(US2 4) and 30% w/w (US2 2.5) loaded samples is that
US2 2.5 sample is higher in amorphous than the US2 4
and, therefore, will be stable for longer as a solid disper-
sion product. This foregoing claim complements the finding
from the release data of BMA achieved at 30 min. As can
be seen in Fig. 8, the release of the drug was increased up
to the 30% w/w drug loading (US2 2.5). With the increase
in the content of the drug, the release seemed to have
decreased possibly due to the drug collapsing into its crys-
talline form. However, anything above 40% w/w drug load-
ed samples showed that the optimum level of drug loading
has been achieved and the sample will no longer exhibit
higher amorphous nature or exothermic response as com-
pared to 30% w/w loaded sample. These data suggest that
the solution calorimetry could be effectively used to distin-
guish different solid dispersion products with varying drug
loadings and be interrelated with the most optimised for-
mulation as a function of the increased release of the drug.
As the name suggests, it is a precision solution calorimetry
technique; therefore, room temperature, method develop-
ment, sample preparation, solvent selection, etc. require
Table 2 Solution calorimetric data of US2 samples






Mean Overall mean SD RSD
BMA 1 0.10026 36.005 35.998 36.00 36.6 0.5 1.4 N/A
2 0.10034 36.947 36.974 36.96
3 0.10036 36.888 36.839 36.86
US2 1 0.10062 − 45.948 − 45.874 − 45.91 − 46.5 0.5 − 1.1
2 0.10064 − 46.869 − 46.847 − 46.86
3 0.10053 − 46.670 − 46.656 − 46.66
US2 1 (PM) 1 0.10013 − 5.951 − 5.936 − 5.94 − 5.4 0.5 − 9.0 − 4.9
2 0.10186 − 4.974 − 4.969 − 4.97
3 0.10071 − 5.369 − 5.356 − 5.36
US2 4 1 0.10072 − 10.823 − 10.809 − 10.82 − 10.9 0.3 − 2.8 − 29.9
2 0.10070 − 10.726 − 10.702 − 10.71
3 0.10050 − 11.293 − 11.277 − 11.29
US2 2.5 1 0.10008 − 15.983 − 15.968 − 15.98 − 16.3 0.6 − 3.9 − 21.6
2 0.10035 − 17.014 − 16.986 − 17.00
3 0.10009 − 15.866 − 15.850 − 15.86
US2 1 1 0.10045 − 14.052 − 14.003 − 14.03 − 14.4 0.4 − 3.1 − 13.2
2 0.10045 − 14.911 − 14.894 − 14.90
3 0.10092 − 14.292 − 14.276 − 14.28
Table 1 Hygroscopicity classification
Classification Weight increase at 80% RH (25 °C)
Non-hygroscopic < 0.2%
Slightly hygroscopic ≥ 0.2 and < 2%
Hygroscopic ≥ 2 and < 15%
Very hygroscopic ≥ 15%
Deliquescent Sufficient water is absorbed
to form a liquid
From [28]
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years of experience to reproduce consistent data especially
in complex systems like solid dispersion, granulated formu-
lations using this technique.
Conclusion
In the current study, US2 was demonstrated as a suitable al-
ternative carrier for the development of the amorphous gran-
ules by means of continuous dry granulation approach. The
drug has been found to exist in its amorphous forms as deter-
mined by DSC, XRPDwhere as both SEM and optical micro-
scopic analyses revealed a homogenous dispersion of the drug
into the carrier matrices due to the intense mixing during the
granulation processing. The analysis conducted via the FTIR
outlines a possible intermolecular interaction between the
drug and the carrier which may have been the underlying
reason of the development of the stable solid dispersions.
The results obtained from the DVS suggest that the formula-
tions are quite stable even at a relatively high drug loading (up
to 50% w/w). Moreover, the results obtained from the novel
SolCal analysis revealed and interrelated the amorphous con-
tents to that of the dissolution of the drug from the formula-
tions very precisely. It is concluded that SolCal can be used as
a powerful tool to determine the amorphous content as a func-
tion of the heat of solution in order to develop stable amor-
phous solid dispersions with enhanced dissolution rates.
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